FDA Approval: Blinatumomab for Patients With B-Cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission With Minimal Residual Disease

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-2337

Related search